All Articles

Data from Phase 1 trials suggest SAB-142 could offer a new approach to treating Type 1 Diabetes, potentially preserving insulin-producing cells without prolonged immunosuppression. The company is now advancing into a pivotal Phase 2b trial.

A growing partnership between a credit union, university, and athletic brand is making a tangible difference in the lives of Phoenix-area students, providing not just footwear, but a foundation for success.

Positive early trial data for Aptose Biosciences’ acute myeloid leukemia treatment, tuspetinib, is tempered by ongoing financial challenges and reliance on a single funding source. Can the biotech survive long enough to bring its therapy to market?

Positive Phase 2 data for Alumis’s envudeucitinib offers a new potential treatment for psoriasis, with a focus on selective TYK2 inhibition. The drug is poised to compete with established biologics and emerging oral therapies.

Senti Bio presents encouraging Phase 1 data for its novel AML therapy, SENTI-202, but faces a critical funding shortfall. Can this innovative gene-circuit technology overcome significant financial headwinds?

Clinical trial advancements and a robust platform for drug discovery position Acrivon Therapeutics as a key player in precision oncology. New data offers hope for patients battling endometrial cancer.

As housing costs rise, manufactured home investor FG Communities expands its footprint in North Carolina, providing crucial affordable options near the major military base of Camp Lejeune. Is this a model for addressing the nation's housing crisis?

GoPro's CEO just made a significant personal investment in the company, signaling confidence in its diversification strategy. But with rivals like DJI launching competitive products, can GoPro maintain momentum?

Biotech firm Trevi Therapeutics reports strong Q3 financials and positive clinical trial data, paving the way for potential first-in-class treatment for chronic cough conditions like IPF and RCC.

Biotech firm Calidi Biotherapeutics reports positive preclinical results for its RedTail platform and lead candidate, CLD-401, alongside a successful funding round. The company aims to revolutionize cancer treatment through systemic targeted genetic medicine delivery.

Aardvark Therapeutics reports positive clinical trial progress for its Prader-Willi Syndrome treatment and unveils promising preclinical data for a novel obesity candidate designed to address limitations of existing GLP-1 RA therapies.

After navigating financial headwinds, Evofem Biosciences reports positive Q3 results, fueled by cost reductions and strategic shifts. Can the company maintain momentum and expand access to critical women’s health solutions?

Biotech firm Equillium has secured up to $50 million in funding to advance its lead candidate, EQ504, a novel therapy targeting ulcerative colitis. The company is betting on a new approach to immune modulation, shifting focus from previous programs.

Molecular diagnostics firm Co-Diagnostics reports widening losses and introduces a non-GAAP metric to assess performance, raising questions about its long-term viability as COVID-19 testing demand wanes.

Pittsburgh is betting on technology to boost its population. A new platform, 'Pittsburgh Tomorrow Pioneer,' uses AI to connect newcomers with resources, aiming to make the city a welcoming hub.

Despite revenue dips, Sera Prognostics is making strides in securing Medicaid coverage for its PreTRM test, aiming to revolutionize preterm birth risk assessment and improve maternal health outcomes.

A new partnership and promising clinical data are positioning Vaxart as a key player in the emerging oral vaccine market, with implications for infectious disease prevention and global access.

Fast-growing logistics provider Armlogi is capitalizing on the booming cross-border e-commerce market, but faces challenges from volatile freight rates and fierce competition. A deep dive into their strategy and industry trends.

Facing a historically underserved market, Daré Bioscience is pioneering a multi-pronged approach – leveraging 503B compounding, securing substantial grant funding, and developing innovative therapies – to address critical gaps in women's healthcare.

Canadian pharma firm BioSyent Inc. prepares to report Q3 & YTD 2025 earnings. A deep dive into the company's growth strategy, industry headwinds, and future outlook in the rapidly evolving specialty pharmaceutical market.